Premium
Biomarkers for Delirium—A Review
Author(s) -
Khan Babar A.,
Zawahiri Mohammed,
Campbell Noll L.,
Boustani Malaz A.
Publication year - 2011
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.2011.03702.x
Subject(s) - delirium , medicine , biomarker , intensive care medicine , risk stratification , prospective cohort study , medline , population , environmental health , biochemistry , chemistry , political science , law
To improve delirium recognition and care, numerous serum biomarkers have been investigated as potential tools for risk stratification, diagnosis, monitoring, and prognostication of delirium. The literature was reviewed, and no evidence was found to support the clinical use of any delirium biomarker, although certain biomarkers such as S‐100 beta and insulin‐like growth factor‐1 and inflammatory markers have shown some promising results that need to be evaluated in future studies with appropriate sample size, prospective designs, and in a more‐generalizable population.